Photo: investing.com
Caribou Biosciences Stock Doubles on Promising Myeloma Therapy Results
Caribou Biosciences stock surged 100% after promising Phase 1 results for its CB-011 therapy in treating relapsed or refractory multiple myeloma, showing a 92% response rate.
- In a cohort study involving 12 patients with relapsed or refractory multiple myeloma, Caribou Biosciences reported a 92% overall response rate for its CB-011 therapy.
- The CaMMouflage Phase 1 trial demonstrated a 75% complete response rate or better, marking a significant clinical endpoint for the companys innovative treatment approach.
- Rachel Haurwitz, CEO of Caribou, emphasized the potential of CB-011 to address the challenges of relapsed multiple myeloma, especially in patients who have undergone autotransplantation.
Why It Matters
The promising results of CB-011 highlight advancements in CAR T cell therapies, offering hope for patients with difficult-to-treat diseases like multiple myeloma and potentially reshaping treatment paradigms in oncology.